The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Narcolepsy is a chronic brain disorder that disrupts sleep-wake cycles. People with narcolepsy may feel refreshed after ...

Global Narcolepsy Treatment market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Growing Awareness. NEWARK, DE, UNITED STATES, January ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support market ...